0.33
price down icon2.86%   -0.0097
after-market Dopo l'orario di chiusura: .34 0.01 +3.03%
loading
Precedente Chiudi:
$0.3397
Aprire:
$0.32
Volume 24 ore:
217.14K
Relative Volume:
0.13
Capitalizzazione di mercato:
$5.80M
Reddito:
-
Utile/perdita netta:
$-19.59M
Rapporto P/E:
-0.0136
EPS:
-24.29
Flusso di cassa netto:
$-16.49M
1 W Prestazione:
-17.44%
1M Prestazione:
-46.18%
6M Prestazione:
-71.30%
1 anno Prestazione:
-96.85%
Intervallo 1D:
Value
$0.32
$0.3499
Intervallo di 1 settimana:
Value
$0.313
$0.3984
Portata 52W:
Value
$0.216
$18.66

Transcode Therapeutics Inc Stock (RNAZ) Company Profile

Name
Nome
Transcode Therapeutics Inc
Name
Telefono
857-301-6857
Name
Indirizzo
6 LIBERTY SQUARE, BOSTON
Name
Dipendente
10
Name
Cinguettio
Name
Prossima data di guadagno
Name
Ultimi documenti SEC
Name
RNAZ's Discussions on Twitter

Confronta RNAZ con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
RNAZ 0.33 5.80M 0 -19.59M -16.49M -24.29
VRTX 467.01 119.87B 10.63B -479.80M -1.35B 13.33
REGN 762.00 83.27B 13.85B 4.65B 3.32B 35.06
ARGX 567.90 33.96B 1.86B -40.29M -1.28B -4.16
ALNY 232.27 30.18B 2.09B -332.26M 16.06M -4.14
BNTX 101.87 24.42B 3.30B -501.07M 1.03B 11.54

Transcode Therapeutics Inc Borsa (RNAZ) Ultime notizie

pulisher
Nov 14, 2024

Transcode Therapeutics Reports Increased Losses Amid Funding Challenges - TipRanks

Nov 14, 2024
pulisher
Nov 14, 2024

TransCode Therapeutics Inc (RNAZ) Quarterly 10-Q Report - Quartzy

Nov 14, 2024
pulisher
Nov 12, 2024

Transcode Therapeutics sends open letter to shareholders - TipRanks

Nov 12, 2024
pulisher
Nov 12, 2024

Next Hydrogen Solutions Inc. Announces Private Placement of Unsecured Convertible Debentures - The Manila Times

Nov 12, 2024
pulisher
Nov 12, 2024

TransCode Therapeutics Open Letter to Shareholders - The Bakersfield Californian

Nov 12, 2024
pulisher
Nov 12, 2024

TransCode (RNAZ) Faces Delisting Risk, Seeks Shareholder Approval for Reverse Split | RNAZ Stock News - StockTitan

Nov 12, 2024
pulisher
Nov 05, 2024

TransCode Therapeutics maintains Nasdaq listing with conditions - Investing.com

Nov 05, 2024
pulisher
Nov 05, 2024

TransCode Therapeutics Announces Nasdaq Extension to Regain Compliance - The Manila Times

Nov 05, 2024
pulisher
Nov 05, 2024

TransCode Therapeutics maintains Nasdaq listing with conditions By Investing.com - Investing.com UK

Nov 05, 2024
pulisher
Nov 05, 2024

TransCode (RNAZ) Maintains Nasdaq Listing Despite Reprimand Over Compliance Issues | RNAZ Stock News - StockTitan

Nov 05, 2024
pulisher
Oct 23, 2024

TransCode advances to phase 1 cancer trial's next stage - Investing.com

Oct 23, 2024
pulisher
Oct 23, 2024

ORIC® Pharmaceuticals Presents Data Further Supporting Potential Best-In-Class Profile of ORIC-114 to Treat EGFR Exon 20 Insertions and Other Atypical Mutations at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics - The Manila Times

Oct 23, 2024
pulisher
Oct 23, 2024

TransCode Therapeutics Announces Safety Review Committee Approval of Second Cohort Opening in Phase 1 TTX-MC138 Clinical Trial Following Favorable Review of Cohort 1 Safety Data - StockTitan

Oct 23, 2024
pulisher
Oct 15, 2024

Form PRE 14A Transcode Therapeutics, For: Oct 15 - StreetInsider.com

Oct 15, 2024
pulisher
Oct 15, 2024

TransCode Therapeutics Inc (RNAZ) is a good investment, but the stock may be undervalued - US Post News

Oct 15, 2024
pulisher
Oct 11, 2024

Tevogen Bio (Nasdaq: TVGN) Stock Recovers After Major Updates - DRP Journal

Oct 11, 2024
pulisher
Oct 11, 2024

TransCode Therapeutics Inc. (NASDAQ: RNAZ) Stock Sees Bullish Move: But Why? - DRP Journal

Oct 11, 2024
pulisher
Oct 11, 2024

BloomZ Inc. (NASDAQ: BLMZ) Stock Rockets On a New Contract - DRP Journal

Oct 11, 2024
pulisher
Oct 11, 2024

TransCode Therapeutics Inc (NASDAQ:RNAZ) stock crossing the finish line today - US Post News

Oct 11, 2024
pulisher
Oct 10, 2024

TransCode Therapeutics Completes Initial Dosing of First Cohort in Phase 1 Clinical Trial with TTX-MC138, a - EIN News

Oct 10, 2024
pulisher
Oct 10, 2024

There is no doubt that TransCode Therapeutics Inc (RNAZ) ticks all the boxes. - SETE News

Oct 10, 2024
pulisher
Oct 10, 2024

TransCode Therapeutics Completes Initial Dosing of First Cohort in Phase 1 Clinical Trial with TTX-MC138, a microRNA-Targeted Technology - The Manila Times

Oct 10, 2024
pulisher
Oct 10, 2024

Tilray Brands Reports Q1 2025 Financial Results - The Manila Times

Oct 10, 2024
pulisher
Oct 07, 2024

RNAZ’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - The InvestChronicle

Oct 07, 2024
pulisher
Oct 07, 2024

TransCode Therapeutics Inc (RNAZ)’s stock chart: A technical perspective - US Post News

Oct 07, 2024
pulisher
Oct 03, 2024

Halozyme (HALO) Stock Surges Amid Positive Earnings and Analyst Ratings - GuruFocus.com

Oct 03, 2024
pulisher
Oct 02, 2024

TransCode Therapeutics Inc’s Market Journey: Closing Weak at 0.49, Down -15.04 - The Dwinnex

Oct 02, 2024
pulisher
Oct 01, 2024

U.S. shares mixed at close of trade; Dow Jones Industrial Average down 0.21% - MSN

Oct 01, 2024
pulisher
Oct 01, 2024

Riding the Waves: A Guide to Investing in RNAZ Stock - The InvestChronicle

Oct 01, 2024
pulisher
Sep 27, 2024

Transcode Therapeutics faces potential Nasdaq delisting - Investing.com

Sep 27, 2024
pulisher
Sep 27, 2024

TransCode Therapeutics Inc (RNAZ): Worth A Small Bite At $0.62 - Stocks Register

Sep 27, 2024
pulisher
Sep 26, 2024

TransCode Therapeutics Begins Dosing Patients in Phase 1 Trial for Metastatic Cancer Therapy - Proactive Investors USA

Sep 26, 2024
pulisher
Sep 26, 2024

U.S. shares mixed at close of trade; Dow Jones Industrial Average down 0.70% - MSN

Sep 26, 2024
pulisher
Sep 25, 2024

TransCode Therapeutics Inc (RNAZ) expanding its growth trajectory ahead - SETE News

Sep 25, 2024
pulisher
Sep 25, 2024

Gaining Ground: TransCode Therapeutics Inc (RNAZ) Closes Higher at 0.42, Up 35.75 - The Dwinnex

Sep 25, 2024
pulisher
Sep 24, 2024

TransCode Therapeutics Inc (RNAZ) presents a great opportunity, but the stock is slightly undervalued - US Post News

Sep 24, 2024
pulisher
Sep 20, 2024

Ratio Review: Analyzing TransCode Therapeutics Inc (RNAZ)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex

Sep 20, 2024
pulisher
Sep 19, 2024

Taking the lead: TransCode Therapeutics Inc (RNAZ) - SETE News

Sep 19, 2024
pulisher
Sep 18, 2024

Recent Insider Activity Could Benefit Ocean Power Technologies (OPTT) - Knox Daily

Sep 18, 2024
pulisher
Sep 18, 2024

W.R. Berkley Corp. [WRB] Investment Appeal on the Rise - Knox Daily

Sep 18, 2024
pulisher
Sep 18, 2024

TransCode begins Phase 1 trial of metastatic cancer treatment By Investing.com - Investing.com Canada

Sep 18, 2024
pulisher
Sep 17, 2024

RNAZ’s Financial Health: Exploring TransCode Therapeutics Inc’s Debt-to-Equity Ratio of 1.79 - The InvestChronicle

Sep 17, 2024
pulisher
Sep 17, 2024

RNAZ’s price-to-sales ratio: A comparative analysis with its peers - US Post News

Sep 17, 2024
pulisher
Sep 17, 2024

TransCode begins Phase 1 trial of metastatic cancer treatment - Investing.com

Sep 17, 2024
pulisher
Sep 17, 2024

TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate - StockTitan

Sep 17, 2024
pulisher
Sep 11, 2024

TransCode reports progress in metastatic breast cancer treatment By Investing.com - Investing.com Australia

Sep 11, 2024
pulisher
Sep 10, 2024

Transcode Therapeutics announces publication of study on TTX-MC138 - TipRanks

Sep 10, 2024
pulisher
Sep 10, 2024

TransCode reports progress in metastatic breast cancer treatment - Investing.com

Sep 10, 2024
pulisher
Sep 10, 2024

Upward Trajectory: TransCode Therapeutics Inc (RNAZ) Posts a Slidee, Closing at 0.26 - The Dwinnex

Sep 10, 2024
pulisher
Sep 10, 2024

TransCode Therapeutics Announces Publication of Study with Lead Therapeutic Candidate Revealing - The Bakersfield Californian

Sep 10, 2024
pulisher
Sep 10, 2024

TransCode Therapeutics Announces Publication of Study with Lead Therapeutic Candidate Revealing Mechanisms Behind Candidate’s Preclinical Efficacy Against Metastatic Cancer - StockTitan

Sep 10, 2024

Transcode Therapeutics Inc Azioni (RNAZ) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$18.98
price up icon 3.66%
$76.97
price up icon 1.45%
$39.51
price up icon 7.22%
$359.21
price down icon 1.11%
$187.69
price down icon 0.81%
$101.87
price up icon 2.16%
Capitalizzazione:     |  Volume (24 ore):